DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 239.8

Change

-5.50 (-2.24)%

Market Cap

N/A

Volume

14.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-20 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.06 (+0.11%)

USD 108.20B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 93.32B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.01 (+0.02%)

USD 86.92B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.65 (+0.27%)

USD 53.24B
VUSA:F Vanguard Funds Public Limited ..

+0.97 (+1.01%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.39 (-0.40%)

USD 51.63B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 51.19B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 41.09B
0ZC:F Zscaler Inc

+0.14 (+0.09%)

USD 37.92B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.29% 84% B 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.29% 81% B- 66% D+
Trailing 12 Months  
Capital Gain 19.63% 72% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.63% 68% D+ 61% D-
Trailing 5 Years  
Capital Gain 62.11% 81% B- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.11% 81% B- 63% D
Average Annual (5 Year Horizon)  
Capital Gain 8.97% 70% C- 68% D+
Dividend Return 8.97% 68% D+ 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.66% 71% C- 91% A-
Risk Adjusted Return 103.65% 98% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike